

Amendments to the Claims

This listing of claims will replace all prior versions of the claims and listing of the claims in the application.

Listing of Claims

1-94. (Canceled)

95. **(Currently Amended)** A therapeutic composition, comprising a mixture of the following isolated polypeptides ~~an isolated polypeptide selected from the group consisting of:~~

(a) an isolated polypeptide comprising the amino acid sequence set forth in SEQ ID NO:6; and

(b) an isolated polypeptide ~~about 30 amino acid residues in length and consisting of comprising at least~~ residues 14-39 of SEQ ID NO:6, or an epitope-containing portion thereof;

wherein said composition is capable of reducing an allergic response to a cat antigen in an individual sensitive to said antigen.

96-101. (Canceled)

102. **(Currently Amended)** The composition ~~A polypeptide~~ according claim 95, wherein at least one of the polypeptides ~~the polypeptide~~ has a stimulation index of at least 4.0 or a positivity index of at least 250, wherein the stimulation index is defined as the ratio of measured proliferation of T cells and antigen presenting cells from a responding individual when exposed to antigen, to the measured proliferation of said cells in the absence of antigen, and wherein the positivity index is defined as the average stimulation index of a population of responding individuals tested multiplied by the percentage of individuals in the population exhibiting a positive response.

103. **(Currently Amended)** The composition A polypeptide according to claim 95, wherein at least one of the polypeptides is produced recombinantly.

104. **(Currently Amended)** The composition A polypeptide according to claim 95, wherein at least one of the polypeptides is produced by chemical synthesis.

105-110. **(Canceled)**

111. **(Currently Amended)** An isolated polypeptide ~~selected from the group consisting of:~~

~~—— (a) an isolated polypeptide comprising the amino acid sequence set forth in SEQ ID NO:6; and~~

~~—— (b) an isolated polypeptide consisting of Fel 31-2 (residues 14-39 of SEQ ID NO:6) and a pharmaceutical acceptable carrier.~~

112. **(New)** A composition comprising the polypeptide of claim 111.

113. **(New)** The composition of claim 112, further comprising a second isolated polypeptide comprising the amino acid sequence set forth in SEQ ID NO:6.

114. **(New)** The composition of claim 111 or 112, further comprising a fragment of a protein allergen comprising the amino acid sequence set forth in SEQ ID NO:6.

115. **(New)** The composition of claim 114, wherein the fragment is capable of stimulating T cells.